SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff and volatile rebound are driving attention, with SOXLs 3x leverage amplifying the swings. Traders are split between buying the dip on continued AI-chip demand and warning that concerns about AI spending, debt, inflation, and competition could make the bounce short-lived.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A sharp selloff without a new company update has intensified attention on SELLASs event-driven Phase 3 REGAL trial, which was last reported at 78 of 80 required overall-survival events; the 80th event triggers the final analysis. Bulls interpret the prolonged wait as a possible sign of extended patient survival, while bears cite the delay and quiet period as reasons for concern, and some traders blame options-expiration pressure and weakness across biotech.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry about debt-financed data-center expansion, CoreWeaves credit risks, and whether AI spending can justify sector valuations. Bulls argue Nebius is being unfairly lumped in despite what they see as a stronger balance sheet and long-term compute demand, while bears expect more downside amid a broader valuation reset.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp market pullback and a strong futures rebound have fueled intense debate over whether the bounce is a genuine recovery or a short-covering bull trap, with traders disputing recurring Black Monday crash calls. Some attribute the rebound to speculation about Russia-related diplomacy and easing oil or yields, while others remain concerned about tech weakness, inflation, and upcoming earnings.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-linked selloff has left traders weighing concerns about AI spending and debt against hopes for a technical rebound. Black Monday crash calls were met with bullish futures and short-squeeze talk, leaving sentiment divided ahead of major tech earnings.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Reported mature ESMO data for Iovances lifileucel-plus-Keytruda combination in first-line melanoma are driving discussion, with traders highlighting durable responses and encouraging progression-free survival. Bulls see support for expansion into frontline treatment, while skeptics note the small cohort and say the randomized Phase 3 trial must confirm the results; some also view the update as largely consistent with earlier data.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Concerns over CoreWeaves debt-financed AI data-center expansion and worsening bond-market signals are driving a sharp selloff, amid broader pressure on AI infrastructure stocks. Traders debate whether financing risks and insider selling outweigh strong AI demand and contracted backlog, with some expecting a rebound and others warning of deeper losses.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is part of a broad debate over market direction amid rising Treasury yields, Fed-rate concerns, and Iran-related oil and inflation risks. Traders are split between bullish calls for continued gains and warnings of a correction, with technical levels and index volatility also drawing attention.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Discussion centers on StarkWares reported quantum-resistant Bitcoin transaction test on mainnet and Starknets broader Bitcoin, privacy, and post-quantum-security ambitions. Supporters see these developments as a long-term differentiator, while skeptics point to STRKs weak price action and past token-supply pressure.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins volatile rebound after a weekend selloff and leveraged-long liquidations has traders focused on whether it can hold key levels. Bulls see a potential short squeeze, while bears warn the bounce could fade into another leg lower.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ABCL 

I think most people don’t realize that the data we have right now, if it holds, is transformative for menopause industry. 

Transformative. That’s not even taking into account breast and prostate and ovarian cancer. It’s a big deal‼️

The pipeline story already has a strong data point. ABCL635 met both primary goals in its Phase 2 trial for moderate-to-severe VMS, and the stock jumped 33% intraday on the readout, near 40% at the peak. 

ABCL635 only entered clinical trials in July 2025 and it&#39;s already AbCellera&#39;s most advanced asset. It still needs a bigger pivotal trial before any filing, and full 12-week data are the next benchmark and it’s this WEEK in a few days🔥 Thursday, October 22, 2026 TMS!!

$ABCL
 is not one molecule with one readout. It is a discovery engine that partners pay to use, across many programmes running at once. A single failure is a data point, not an ending. That is a different risk shape than single asset biotech.

Stonk Trades

StockTwits for iOS

AbCellera Biologics Inc

 

I think most people don’t realize that the data we have right now, if it holds, is transformative for menopause industry. 

Transformative. That’s not even taking into account breast and prostate and ovarian cancer. It’s a big deal‼️

The pipeline story already has a strong data point. ABCL635 met both primary goals in its Phase 2 trial for moderate-to-severe VMS, and the stock jumped 33% intraday on the readout, near 40% at the peak. 

ABCL635 only entered clinical trials in July 2025 and it's already AbCellera's most advanced asset. It still needs a bigger pivotal trial before any filing, and full 12-week data are the next benchmark and it’s this WEEK in a few days🔥 Thursday, October 22, 2026 TMS!!




 is not one molecule with one readout. It is a discovery engine that partners pay to use, across many programmes running at once. A single failure is a data point, not an ending. That is a different risk shape than single asset biotech.